A number of studies have shown that CD133 is a marker of cancer stem/progenitor cells [30,40,41], and functional assays of CSPCs have revealed that enriched CD133 subpopulations from ovarian cancer tissue are indeed CSPCs [30,40-44]. This evidence concerns the gene PROM1 and ovarian carcinoma.